Diffúz nagy B-sejtes limfóma (DLBCL): vizsgálatok itt: Kína
133 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaSelinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 50
- Run by
- Ruijin Hospital
See details and how to joinNCT06062641 - 2. fázisTaking peopleCD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Where
- Beijing
- Életkor
- 14 év to 85 év
- People
- 100
- Run by
- Beijing Tongren Hospital
See details and how to joinNCT06081478 - 2. fázisTaking peopleA Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
- Where
- Jinan, Nanchang
- Életkor
- 18 év to 70 év
- People
- 31
- Run by
- Shandong Cancer Hospital and Institute
See details and how to joinNCT05933967 - No phaseTaking peopleFrontline of ASCT in High-risk DLBCL
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 175
- Run by
- Peking University People's Hospital
See details and how to joinNCT05831865 - 1. fázisTaking peopleCD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
- Where
- Hangzhou, Ningbo
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Ningbo No. 1 Hospital
See details and how to joinNCT05659628 - 2. fázisTaking peopleEvaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 50
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT05552937 - No phaseTaking peopleR-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
- Where
- Changchun
- Életkor
- 18 év to 75 év
- People
- 64
- Run by
- oubai, MD/PhD
See details and how to joinNCT05040555 - No phaseCsak meghívásosFollow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 407
- Run by
- Chinese Academy of Medical Sciences
See details and how to joinNCT04491721